News from the Danish Medicines Agency
-
Suspicion of rare eye condition from Ozempic use to be investigated further
| 17 January 2025 |
The Danish Medicines Agency will request the European Pharmacovigilance Risk Assessment Commit-tee, PRAC, to assess two new Danish register-based studies from the University of Southern Denmark. The studies point to a potential increased risk of a rare eye condition, NAION, in patients receiving the diabetes medicine Ozempic.
-
EU one step closer to electronic product information
| 16 January 2025 |
In 2023-2024, the Danish Medicines Agency participated in a pilot set to pave the way for using electronic product information (ePI) in favour of the printed package leaflets provided in the medicine package and the printed product information for healthcare professionals.